Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
13G/A What do you say about this?? Who are they?
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6412220
PP, ok this wasn't supposed to happen, I bought at .10 and ask drops to .095..lol
The Volume seems to be increase here, makes me wonder.
What's the feeling here about why this is at .10?
Been doing some DD on this, and going to start a position next week.
PP, Where is the quote from?
(PKTX) Protokinetix..
Cell therapy is one of the fastest growing approaches to the treatment of disease. The survival of cells is an essential component for the success of these therapies. Protokinetix...has a patented family of molecules (AAGP(TM)) that have clearly demonstrated a superior ability to protect cells and tissues subjected to hostile conditions. This collaboration will provide a platform to develop cell preservation formulations for specific applications of AAGP(TM) in a wide range of cell and tissue therapies.
patience imo..nice grabs imo hope ta get some of these down here myself asap!!
PKTX...It is amazing..Just amazing..I got my order filled for 31K @ 0.10 and it still went down that much today..What the heck!!
Protokinetix's CONTROLLED LABORATORY TESTS >>
AAGP™ testing is conducted to international standards in outsourced research laboratories in North America and Europe.
All tests are designed to explore both the safety and effectiveness of AAGP™ when challenged to enhance the health and extend the life of cells.
AAGP™ STABILITY TESTS
AAGPs™ are tested for non-toxicity and stability.
AAGP™ molecules have remained stable when subjected to three tests:
pH ranging from a strong acid level of 1.8 (stronger than stomach acid) to a strong alkali level of 13.8. (the pH scale is calibrated from 1, highly acidic, to 14, highly alkali)
Enzymatic action using protease, which targets the amino acid bonds, and glycosidase, which targets the sugar molecules.
Temperatures ranging from -196°C (cryopreservation) to +37°C (body temperature).
AAGP™ TOXICITY TESTS >>
Cells that have been exposed to AAGP™ at low and high concentrations have remained viable. A common viability test used on cell cultures using trypan blue dye exclusion method has been used to show AAGP™ non-toxicity.
STRESS TESTS ON CELL LINES >>
Cell lines are selected for their high level of sensitivity.
Cell lines are also selected for their potential role in adding value in medical applications, enhancing health and extending life.
All tests are designed to explore how cells from different cell lines act biologically in the presence of AAGP™ when subjected to health and life threatening inflammatory stress conditions and agents.
Results Summary:
In every test the cells that were in the presence of AAGP™ had a higher survival and viability rate than the controls. The overall effect of AAGP™ is to protect, preserve and in some cases to repair. Anti-oxidant and anti-inflammatory effects appear to be at work. AAGP™ appears to enhance heath and extend cell life.
CELL LINES TESTED >>
Stem Cells (Human)
Whole Blood Cells
Blood Platelet Cells
Heart Tissue
Hela (Cancer) Cells
Kidney (KB and Vero) Cells
Adult Skin Fibroblast Cells
Heart Cells (Cardiac Myocites)
Liver Cells (Hepatocites)
Embryonic Skin Fibroblast Cells
Islet Cells (Pancreatic)
Stem Cells (Mouse)
STRESS CONDITIONS AND AGENTS >>
Temperature
· Temperatures ranging from -80° C to +37° C
UV-C Radiation
· This is harsh sterilizing radiation
· 254 Nanometer Wavelength
Oxidation
· Hydrogen Peroxide (H202)
· Powerful Oxidant
Starvation
· Serem Free Culture Media
· Food / Growth / Nutrients Factors (Fetal Bovine Serum) withheld
Inflammation
· Interleukin 1 Beta, a standard agent for stimulating inflammation in cell testing
*All of the above tests are also considered to cause inflammation
BIO-SCREENING CONTROL LAB TESTING >>
AAGP™ testing is conducted to international standards in outsourced research laboratories in North America and Europe.
All tests are designed to explore both the safety and effectiveness of AAGP™ when challenged to enhance the health and extend the life of cells.
AAGPs™ are tested for non-toxicity and stability.
PR NEWS Release..Yes, I know I'm alittle late..PRESS RELEASE >> FEBRUARY 19 - 2009
ProtoKinetix’ AAGP™ is Critical for Stem Cell Therapy
PROTOKINETIX INC. (PKTX: OTCBB)
Vancouver, British Columbia, February 19, 2009
Protokinetix’ (PKTX) results over the last 2-years have clearly shown the vital role that AAGP™ can play in this exciting disease treatment arena. Support for stem cell research has never been stronger and continues to grow. This growth will accelerate as successful results are announced.
One of the most important ingredients for the success of this therapy is the recovery of the maximum number of viable stem cells after storage. These extremely delicate cells typically have a very low yield after cryopreservation. AAGP™ testing that has been conducted on stem cell preservation at all temperatures has shown an impressive increase in survivability and viability.
In summary, over the past 24-months, AAGP™ has demonstrated a remarkable increase in viable cell recovery at temperatures ranging from -196?C (cryopreservation) all the way to 37?C (body temperature). These results have been consistent regardless of the source of the stem cells. As an example, AAGP™ has been independently tested as a protective agent in the cryopreservation (-196?C) and subsequent thawing of umbilical cord blood in low concentrations of AAGP™ (4mg/ml). The resultant analysis revealed a more than double average increase over the control group (cells not protected with AAGP™) in the yield, following thawing.
About ProtoKinetix
nice lil move today may it continue!)eom
You still around this? Ya got a new friend if so lol..eom
interesting will be watching close..eom
PKTX PR News..January 15, 2009 11:02 AM Eastern Time
ProtoKinetix’ Joint Venture to Produce Exclusive Combination AAGP™ and Co-enzyme Q10 Skin/Health Care Product Line
VANCOUVER--(BUSINESS WIRE)--Ross Senior, President and CEO of ProtoKinetix Inc. (PKTX), announces the formation of a Joint Venture with Zymes LLC to commercialize a unique new product line. Zymes is a world leader in the production of high quality Co-enzyme Q10, a well recognized and potent anti-oxidant. Zymes’ Co-founder and Chief Scientific Officer, Dr. Bruce Lipshutz, has patented a method for producing water soluble CoQ10 (The Lipshutz Method) which has been proven to increase the absorption into cells and tissues for protection and repair. This Joint Venture will combine the knowledge and expertise of two world renowned sciences from France (Dr. Geraldine Deliencourt) and the United States (Prof. Bruce Lipshutz, U of C, Santa Barbara).
Over the last few years extensive tests by PKTX subjected skin cells to harmful oxidative stresses of ultra violet radiation and hydrogen peroxide. The tests showed AAGP™ to be a powerful anti-oxidant, however the combination of these two molecules (AAGP™ and CoQ10) provided significantly greater protection from the harmful oxidative stresses than could otherwise be attained from either molecule acting individually. ProtoKinetix’ news release of January 26, 2006 provides a summary of the dramatic results achieved combining these two molecules for cell and tissue protection. UV radiation and oxidation damage cells, tissues and organs and are major contributors to aging of the skin.
The Joint Venture is founded on the unique combination of the molecular structures, bioactivities and health care attributes of PKTX’ AAGP™ and Zymes’ CoQ10. In addition to skin care, other targeted applications include stem cell preservation and survival, ischemia, reperfusion injury and wound healing. The diversity of applications underscores the value of the AAGP™ family of molecules.
Ross Senior says, “We are extremely pleased to partner with Zymes and are confident about the success of the venture and the benefits for our shareholders.”
(PKTX) PR NEWS...ProtoKinetix Signs Collaborative Agreement with Multi-National Corporation
VANCOUVER, British Columbia, November 17, 2008 /PRNewswire-FirstCall/ -- ProtoKinetix, Inc. , a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)), announced today that it has entered into a collaborative research agreement with a global multi-billion dollar company that provides products and services to pharmaceutical and biotechnology companies, as well as academic and research institutions. This company is recognized worldwide as one of the leading innovators of cell and tissue engineering. Due to the extreme sensitivity and highly competitive nature of this industry, the company has requested that, at this time, their name be kept confidential.
ProtoKinetix has a patented family of molecules (AAGP(TM)) that have clearly demonstrated a superior ability to protect cells and tissues subjected to hostile conditions. This collaboration will provide a platform to develop cell preservation formulations for specific applications of AAGP(TM) in a wide range of cell and tissue therapies.
Cell therapy is one of the fastest growing approaches to the treatment of disease. The survival of cells is an essential component for the success of these therapies.
(PKTX) PR NEWS...PRESS RELEASE >> OCTOBER 28 - 2008
ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
PROTOKINETIX INC. (PKTX: OTCBB)
VANCOUVER, BRITISH COLUMBIA, NOVEMBER 10, 2008
VANCOUVER, British Columbia, Nov. 10 /PRNewswire-FirstCall/ -- ProtoKinetix Inc. (OTC Bulletin Board: PKTX - News), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)) announced today that its Director of Science Dr. Geraldine Deliencourt has received results of tests conducted by a major independent laboratory in France to determine the biological activity of AAGP(TM) on the selectin inflammation pathway. The highly specific tests conducted on selectin showed 100% adhesion inhibition. Diseases such as Alzheimer's, Chron's, diabetes, arthritis, cancer and cardiovascular problems are among the many life-threatening conditions treated with anti-inflammation and selectin inhibition therapies.
These results are consistent with previous tests conducted using extremely hostile stresses. Repeatedly, the presence of AAGP(TM) has shown its ability to protect cells under the most adverse of conditions. Dr. Deliencourt said, "The results obtained broaden the impact and scope of the applications of AAGP(TM). They will also help us clarify the mechanism of action of AAGP(TM) and seem to be consistent with all of the previous results we have obtained." She further explains that these results indicate that AAGP(TM) could be both an adhesion inhibitor and an anti-oxidant.
Ross Senior, President and CEO of ProtoKinetix, said, "The control of inflammation is of vital importance to the treatment of a number of immune complex mediated diseases. AAGP(TM) continues to demonstrate its potential to become a major contributor in the successful treatment of a wide range of health problems."
Anyone would have to admire the efforts of the CEO for this company regardless whether or not the efficacy of AAGP is ever proven to be good for anything.
I like the chances for 2 or 3 dollars here within the next year.
PKTX PR News...ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base
Tuesday 10/14/2008 8:31 AM ET - Cnw Group
Related Companies
Symbol Last %Chg
PKTX 0.19 26.67%
As of 3:56 PM ET 10/14/08
ProtoKinetix (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)), announced today that it has partnered with OTC Financial Network (OTCFN), a division of National Financial Communications Corp. (NFC), to direct a comprehensive shareholder awareness campaign.
"ProtoKinetix' AAGP(TM) platform technology is ideal for a number of applications in the skin care/cosmetics, cellular therapy, blood preservation and pharmaceutical industries," said Geoffrey Eiten, president of NFC. "Last month, ProtoKinetix entered into its first licensing agreement to provide AAGP(TM) as the primary active ingredient in an anti-inflammatory cream for the sports injury market. This contract is one of several in the pipeline that position ProtoKinetix on a path to commercial success. We look forward to introducing the Company and its world-class management team to the financial community."
"We've selected to partner with OTCFN to increase our market awareness and widen our shareholder base," said Ross L. Senior, President and CEO of ProtoKinetix Inc. "We are excited to be working with a financial communications firm that has a well respected track record. We believe we can effectively enhance shareholder value by partnering with companies that offer the technical, marketing and distribution expertise to bring AAGP(TM) applications to market."
Stem Cell Research
--------------------------------------------------------------------------------
Stem Cell Breakthrough
Over 1000 Patients Treated for Multiple Diseases. Taking Patients!
"These cells will be tremendous in drug discovery," said John McNeish, executive director of Pfizer's global research and development arm in an interview reported by Reuters.
McNeish, described by Pfizer as "one of the world's leading stem cell scientists", has many years experience in using stem cells, particularly as screening tools in drug discovery. He gave an interview at the World Stem Cell Summit in Madison, Wisconsin, earlier this week where he revealed that some of the first applications of stem cell technology at Pfizer will be in drug testing.
Pfizer, who lead the world in blockbuster drug sales (last year they sold over 10 billion dollars' worth of their cholesterol-busting statin Lipitor), is also to set up a new standalone regenerative medicine unit in Cambridge in the UK. This centre will focus on diseases of the central nervous system and ophthalmology, while McNeish's US-based unit will focus on diabetes and heart disease.
Pfizer hope to build up a team of 50 to 60 scientists specializing in stem cell research, working to develop new stem cell therapies. They will collaborate with academics and the smaller biotech companies, which to date have led the field.
McNeish said that iPS cells will help Pfizer researchers "understand personalized medicine, genetic variation, ethnic populations, what biomarkers to follow".
He said he hoped it will be possible one day to use compounds to coax stem cells in the body to repair injuries. For now, they will use them to help decide which drugs are likely to be safe, said the Reuters report.
One example would be to stimulate the production of new heart cells to repair tissue damage in patients with chronic heart failure. Even a 3 or 4 per cent improvement could make a significant difference to a patient's quality of life, said McNeish.
Pfizer is not the only drug company to start looking at stem cell technology as a source of new therapies. Last year GlaxoSmithKline (GSK), AstraZeneca and Roche Holding launched a new initiative "Stem Cells for Safer Medicines" for using stem cells to test new drugs. And GSK recently announced a 25 million dollar joint project with Harvard Stem Cell Institute to look into the drug development potential of stem cell technology.
Scientists gathered at the World Stem Cell Summit pushed for more research into stem cells.
James Thomson, the first scientist to isolate stem cells ten years ago, was also at the summit and spoke of new opportunities for stem cell research to develop therapies against cancer, diabetes, multiple sclerosis and Parkinson's. Delegates also discussed legislation, bioethics and politics.
The summit also dealt with the uneasy tension between iPS and embryonic stem cell research, where the latter involves destroying human embryos. According to a report by Channel 3000 Wisconsin TV, Governor Jim Doyle gave a speech with Thomson on this, saying they both supported continuing research into both types of stem cell. Thomson said he believed the future was in iPS cells but it wasn't here yet.
"If they're identical to embryonic stem cells, then everything we're doing with embryonic stem cells today will apply directly to these new stem cell lines," said Thomson, however:
"If they're fatally flawed in some way, not clinically relevant, then everything we're doing with embryonic stem cells will apply to embryonic stem cells and we won't waste any time," he said.
"We can not allow once again a fight over politics and over one religion versus another religion to get into the middle of a scientific issue of where science should lead us and where the research should go," added Doyle.
In its Stem Cell Research Policy, Pfizer recognizes that "human embryonic stem cells may provide even greater potential due to their increased ability for self-renewal and capacity to form a wide variety of cells and tissues". The company says it acknowledged the sensitive issues raised by this research and that proper standards are necessary to safeguard not only the moral but also the public view
COMMERCIAL APPLICATIONS-Protokinetixs (PKTX)...>> STEM CELLS AND AAGP™
Stem cells are one of the most promising areas of R&D in biotechnology today. Medical Scientists believe that stem cells offer the potential to cure or mitigate a host of pervasive and debilitating diseases and conditions such as multiple sclerosis, Parkinson’s Alzheimer’s, and diabetes. They also believe that stem cells can be used to repair damaged tissues or cells caused by caused by injuries to organs, limbs, and the spinal cord.
Stem cells are usually small in number, expensive to collect and have a delicate constitution. They are meant to live inside the body, however medical research and development requires them to live and function outside the body. This environment, along with the processes of collection, purification, separation, expansion, cryopreservation and thaw are all stresses that tend to cause stem cells to die or become dysfunctional in some way. Therefore the inventory of healthy stem cells is of significant importance and presents challenges for researchers and clinicians.
AAGP™ has demonstrated an ability to increase the inventory of viable stem cells. In laboratory controlled tests AAGP™ treated cells have survived harsh environmental stresses such as cryopreservation hydrogen peroxide oxidation, inflammation from interleukin 1Beta, UV-C radiation, and nutrient deprivation.
New Stem Cell News..PKTX will be a partner in this process, in to the future(IMHO)...
Stem Cell Breakthrough...
Stem cell research is the next great leap in medicine. In the future, new tissue grown in a laboratory could replace a failing heart, or new cells take the place of damaged cells in the brain. Rather than using stem cells from embryonic sources, which opens difficult ethical and complicated scientific issues, scientists have been looking to adult human stem cells, culled from a person's own body. Adult stem cells are now being cultivated from various tissues in the body -- from skin, bones and even wisdom teeth.
At the forefront in this research is a team of scientists from Tel Aviv University and Scripps Research Institute in California. They recently reported a breakthrough on a new classification system for identifying pluripotent stem cells in human tissue. News about this system recently appeared in the prestigious scientific journal Nature.
Pluripotent stem cells have the potential to differentiate into every distinct cell type in the developed human body. They hold great promise for use in drug development and the treatment of many devastating disorders.
Avoiding Cultural and Religious Controversy
"There is a huge interest in scientists taking skin cells or other body cells of a person, and then turning them into stem cells for creating new neurons in the brain," says Igor Ulitsky, a Ph.D. student at Prof. Ron Shamir's lab in the Blavatnik School for Computer Science, Tel Aviv University, who pioneered some of the research techniques. "Using a person's own stem cells is both ethically acceptable, and in some cases even better for regenerating tissue than embryonic stem cells."
Tel Aviv University research played a central role, creating new bioinformatics algorithms to analyze the data and put together the pieces of the puzzle. The result is, in effect, an encyclopaedia describing different stem cell types and their characteristics.
Before this breakthrough, made possible by international collaboration, scientists were baffled by how to distinguish different stem cell types. "Our lab helped devise a method to classify stem cells according to their machinery," Ulitzky explained. "Stem cells have small but significant differences between them, and knowing the potential properties of each kind is valuable for advancing this promising field of research."
An Ethical and Scientific Test
With rapid advances in the field of stem cells -- including methods to induce pluripotence in various cells, such as those that comprise human skin -- the question of how to define pluripotence has become increasingly critical. This is especially the case for human cell lines, which for both ethical and scientific reasons cannot be treated as those from other species.
"There has been no ethically acceptable equivalent test that could prove pluripotency in human cell preparations," said Franz-Josef Mueller, M.D., an investigator at Scripps. "Many have been purported to be multi- or pluripotent, but there has been no practical way to define pluripotency in human cells."
Using a collection of about 150 human stem cell samples, the researchers created a database of global gene expression profiles and discovered that all of the pluripotent stem cell lines showed a remarkable similarity in the analysis, while other cell types were more diverse.
The analysis by Shamir's lab revealed a protein-protein network common to pluripotent cells, pointing to what may be one of the key building blocks of the machinery that enables these transformative cells to differentiate into multiple cell types. Next, the researchers plan to investigate the regulation of this protein network and how it might be used to advance the development of human gene therapies.
(PKTX)..We got a contract!!!PR News.PRESS RELEASE >> SEPTEMBER 03 - 2008
Protokinetix Contracted to Produce AAGP™ for New Product Launch
ProtoKinetix Inc. (PKTX) is pleased to announce their first commercial contract to manufacture and provide AAGP™ as the key active ingredient in a topical anti-inflammatory cream. This new product is expected to be launched within the next few months by the manufacturer of IB Relief, a leader in sports injury relief. The launch will be greatly enhanced by the use of proven channels of distribution to maximize their share of this multi-billion dollar market.
MEKT, LLC, the parent company that produces IB Relief, is a privately held pharmaceutical firm that specializes in topical cream products for pain management. This market, in the U.S. alone, is a $22 billion business growing at 6.6% yearly. MEKT entered into a License Agreement with ProtoKinetix after an extensive evaluation of the testing that has been completed on AAGP™. The formulation and testing of this new product will commence within the next month.
Ross Senior, President and CEO of ProtoKinetix states, “this will be the first of many commercial applications for the powerful and versatile family of AAGP™ molecules. The list of companies actively conducting trials using AAGP™ is growing.”
.
(PKTX)...Just because it's Friday, the 29th...The last day of the summer investment period before the "Big Boyes" come back to roost(holiday)...Labor Day special??? Do we need to get the Wallets out, yet!!!! Just an question, to the board at Protokinetixs
(PKTX, can help prolong Stem cells,IMHO)
Limbs Saved By Menstrual Blood Stem Cells
Article Date: 19 Aug 2008 - 2:00 PDT
New Stem Cell Treatment
High standard German clinic treats degenerative diseases.
Cells obtained from menstrual blood, termed 'endometrial regenerative cells' (ERCs) are capable of restoring blood flow in an animal model of advanced peripheral artery disease. A study published in BioMed Central's open access Journal of Translational Medicine demonstrates that when circulation-blocked mice were treated with ERC injections, circulation and functionality were restored.
Critical limb ischemia, an advanced form of peripheral artery disease, causes approximately 150,000 amputations per year in the US. Currently there are no medical or surgical interventions that are effective in the advanced stages of the disease. ERCs are cells taken from menstrual blood that are capable of forming into at least 9 different tissue types, including heart, liver and lung. Their discovery won the 'Medicine Research Award of the Year' award for BioMed Central's Research Awards in 2007.
Dr. Michael Murphy, a vascular surgeon from Indiana University and lead author of this study has already performed clinical trials with adult stem cells for patients with peripheral artery disease. He stated, "The advantage of ERCs is that they can be used in an 'off the shelf' manner, meaning they can be delivered to the point of care, do not require matching, and are easily injectable without the need for complex equipment."
The experiments were performed as a collaboration between University of Western Ontario, Scripps Research Institute, Indiana University, and several other academic centers. The ERC cell population is currently being developed by the US publicly traded company Medistem Inc, who supported these studies.
"We are proud of assembling such a strong, clinically experienced team to contribute to these studies" said Dr. Thomas Ichim, CEO of Medistem. "Dr. Ewa Carrier and Suman Kambhampati are hematologists who use stem cells on a regular basis, Dr. Angle is a vascular surgeon, who like Dr. Murphy sees CLI on a daily basis, and Dr. Amit Patel has performed numerous cardiac stem cell clinical trials. With such a team that understands not only the science, but also the practical implementation, we feel we are well positioned to translate this discovery into a practical therapy in the near future".
Dear Folks..PKTX..Look up the term >>>>Death Cross
A crossover resulting from a security's long-term moving average breaking above its short-term moving average or support level.
As long-term indicators carry more weight, this trend indicates a bear market on the horizon and is reinforced by high trading volumes. Additionally, the long-term moving average becomes the new resistance level in the rising market.
(PKTX)I can sleep better tonight knowing just Tuesday..It took 130K bought shares to move PKTX stock up 20 plus %, to 0.27.. and today..With just 370 shares,(YES, 370 SHARES) you can send this stock down 18 plus % to 0.22 and with luck, a total of 1,170 shares, bought..PKTX shot up to 0.25, still a -7.4%...Mommy..What the heck!!!Where's the BLUE LIGHT special!!!
(PKTX)WOW...What a start and what a finish today..It's like getting a haircut cut(Mafia style)with a shotgun...
PKTX'S COMMERCIAL APPLICATIONS >> STEM CELLS AND AAGP™
Stem cells are one of the most promising areas of R&D in biotechnology today. Medical Scientists believe that stem cells offer the potential to cure or mitigate a host of pervasive and debilitating diseases and conditions such as multiple sclerosis, Parkinson’s Alzheimer’s, and diabetes. They also believe that stem cells can be used to repair damaged tissues or cells caused by caused by injuries to organs, limbs, and the spinal cord.
Stem cells are usually small in number, expensive to collect and have a delicate constitution. They are meant to live inside the body, however medical research and development requires them to live and function outside the body. This environment, along with the processes of collection, purification, separation, expansion, cryopreservation and thaw are all stresses that tend to cause stem cells to die or become dysfunctional in some way. Therefore the inventory of healthy stem cells is of significant importance and presents challenges for researchers and clinicians.
AAGP™ has demonstrated an ability to increase the inventory of viable stem cells. In laboratory controlled tests AAGP™ treated cells have survived harsh environmental stresses such as cryopreservation hydrogen peroxide oxidation, inflammation from interleukin 1Beta, UV-C radiation, and nutrient deprivation.
PKTX..PR NEWS..
Symbol Last %Chg
PKTX 0.29 3.57%
As of 1:43 PM ET 7/31/08
ProtoKinetix Inc. (OTCBB:PKTX) is pleased to announce that the TF Chem scientific team, on the behalf of ProtoKinetix, has synthesized a new AAGP(TM) derivative. TF Chem, headed up by ProtoKinetix' Chief Scientist Dr. Geraldine Deliencourt, has successfully developed a prototype derivative of AAGP(TM). It is confidently expected that this prototype derivative will significantly enhance the already powerful preservative characteristics of AAGP(TM). Advanced Nuclear Magnetic Resonance (NMR) analysis has confirmed the successful structure of this prototype molecule. Dr. Deliencourt says, "This new structure has the potential to increase AAGP(TM) bioactivity by a factor of over one hundred times."
The value of this new derivative will come from a substantial gain in the protective mechanism of AAGP(TM) which will lead to a sizable decrease in concentrations required by each application. The effectiveness and efficiency gains will be quantified in biological evaluations over the next few weeks. Highly sensitive cells (such as human embryonic stem cells) require the lowest possible concentrations in their preservation and treatment. Therapeutic applications are best served by low concentrations of biologically active components.
These low levels of concentration will be of vital importance to all segments of the pharmaceutical, cell therapy, blood preservation and skin care industries. Minimal concentration requirements of AAGP(TM) will also enable ProtoKinetix to enter into new therapeutic applications.
About ProtoKinetix
ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP(TM)) for medicine and the biotechnology and cosmetic industries. PKTX is currently in collaboration with major corporations and institutions who have contacted the company about the broad range of applications for AAGP(TM) products.
For more information, on ProtoKinetix please visit our website at: www.protokinetix.com
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
Ross L. Senior, President and CEO
SOURCE: ProtoKinetix, Inc.
ProtoKinetix Inc.
Dear Folks...Yes, reading PKTX filings sucks air but most of what is written in PKTXs filings is boiler-plate provided by the the SEC to legally protect everyone..Some positive information that Protokinetixs has is a world-wide patent for AAGP, it is non-toxic, they have yet to have a negative test result. We might not have a contract yet but PKTX has many companies in many different application areas that are interested... And yes, PR News would be nice...I guess(IMHO)if we were looking for something with less risk, maybe Googles should have been the one to pick...(MHO)I feel, we have a very exciting company here, with earth shaking products..
Are we there? Are we there???
(PKTX).. Someone wake me when this thing(down trend) is over..Thanks, good nite....
Dear Quality...I agree with your post 100%.. I'am on the side lines for now. In a holding pattern, as some would say.. Reading Protokinetixs filing, could conjure up some negative thoughts if I was thinking about investing in PKTX.. Again, you are right and this baby could go either way...Hopefully to the moon. Take care..
pp, right now this company let alone the stock, has absolutely nothing to offer and they are honest about it in their filings.
i don't know how far your neck is in this stock in terms of whether or not you are overextended but stay mindful of the old adage, if something seems too good to be true it prolly is too good to be true and false.
Again, most penny stocks go belly up and just stop trading. Sure occasionally you hit a home run, but that's the exception not the rule. So if you are in too far, sell off some of your stock.
Let's toast to the possibility of a home run but lets not get drunk with irrational exuberance.
Dear Folks..Take a minute..an hour, a day...to think about this stock and what it has to offer once it goes to market..It's a HOLD or Accumulation stock(IMHO)...More patience is required.. But great things will come to those who wait!
(PKTX)..I hope everybody has a "Great" 4th of July weekend.. Remember.. FREEDOM is what it's all about, people!
pp
you are right anything is possible, including waking up one morning and see it halted forever for no apparent reason. That happens all the time in penny stocks.
I'm not being pessimistic here and i am a PKTX shareholder and think we could go up substantially from here. All i am doing is cautioning you on over accumulating at this or any level. Penny stocks are the wild wild west. You can't apply TA to them, you have no idea why they go up or down, they just do and finally most go out of business. Buyer beware!
Dear Qualitylifestyle..Anything is possible with Protokinetixs until we go to market... People on the short term, people that don't see any direction, there are alot of angles that can make this stock go south...But on the other hand, there are so many positives to make this stock so earth shaking exciting!! It's again, like in the past few years(PR NEWS)for PKTXs is REAL SLOW...I have been sending E-mails all the time to the people in Canada(I was told they are working on it).. Once I get the E-mail address in D.C., They will get some mail too... If the stock does goes lower, with all PKTXs discoveries and research under their belt, watch it and accumulate(IMHO).. take care.
PP, its going back to 8 cents
for now. stop accumulating or you will lose your arse.
So what!!! Just put the hammer down, BABY!! Keep accumulating until something more positive comes...(MHO)like signing of a contract, DUDE!
Dear Folks..(PKTX)I know what you're thinking. (1)Is it Oct. "07" all over again, somebody in the back room shorting stock again..(IMHO)..(2)Is it the Darn Day Traders having fun again..Or is it Door #3, close to a signing(again my mho)with a cosmetic company...Buy on the dips!!(IMHO)
(PKTX)...Don't you hate it. You think it's Oct."07" again..You have the parachute on! Ready to ride the stocks down, for some, it's bargin time...Yes people, somebody made some jack today and had a good laugh to boot. Hope you were one of the lucky few, who bought on the dip!
(PKTX)..I hope I don't come off as being negative just because the CCI and Wm% is really low,(It's time to accumulate,)and the aroon is going bearish..(What the hay)!!It's when I watch the latest "James Bond" action movie with Daniel Craig and I'am told, "You're behind times, Dude...REALLY, Do you mean Protokinetixs and myself, need to come up to date with "REAL TIME" date line news...YES, we need some new "Protokinetix's PR NEWS", BABY.....
Stem cell as long as is not embryonic may help people enhance the quality of their lives but no amount of stem cell research can prevent mortality in humans which is 100%. The lady in the article made the point that only through Jesus Christ can you have prolonged life beyond your years here on earth. Keep posting pp, i read all your stuff. It's all good.
PKTX.. I post articles on stem cell research because (IMHO) Protokinetix will and has greatly help with the on going research by doubling the life span of the stem cells, (MHO)which I hope, will bring quality of life to everybody...Stem cell researchers give old muscle new pep...
- The old muscle got a shot of youthful vigor in a stem cell experiment by bioengineers at the University of California, Berkeley, setting the path for research on new treatments for age-related degenerative conditions such as muscle atrophy or Alzheimer's and Parkinson's diseases.
In a new study to be published June 15 in an advanced online issue of the journal Nature, researchers identified two key regulatory pathways that control how well adult stem cells repair and replace damaged tissue. They then tweaked how those stem cells reacted to those biochemical signals to revive the ability of muscle tissue in old mice to repair itself nearly as well as the muscle in the mice's much younger counterparts.
Irina Conboy, an assistant professor of bioengineering and an investigator at the Berkeley Stem Cell Center and at the California Institute for Quantitative Biosciences (QB3), led the research team conducting this study.
Because the findings relate to adult stem cells that reside in existing tissue, this approach to rejuvenating degenerating muscle eliminates the ethical and medical complications associated with transplanting tissues grown from embryonic stem cells.
"We are one step closer to having a point of intervention where we can rejuvenate the body's own stem cells so we don't have to suffer from some of the debilitating diseases associated with aging," said the study's lead author, Morgan Carlson, a recent Ph.D. graduate of Conboy's lab.
The researchers focused on the interplay of two competing molecular pathways that control the stem cells, which sit next to the mature, differentiated cells that make up our working body parts. When the mature cells are damaged or wear out, the stem cells are called into action to begin the process of rebuilding.
"We don't realize it, but as we grow our bodies are constantly being remodeled," said Conboy. "We are constantly falling apart, but we don't notice it much when we're young because we're always being restored. As we age, our stem cells are prevented, through chemical signals, from doing their jobs."
The good news, the researchers said, is that the stem cells in old tissue are still ready and able to perform their regenerative function if they receive the appropriate chemical signals. Studies have shown that when old tissue is placed in an environment of young blood, the stem cells behave as if they are young again.
"Conversely, we have found in a study published last year that even young stem cells rapidly age when placed among blood and tissue from old mice," said Carlson, who will stay on at UC Berkeley to expand his work on stem cell engineering either as a QB3 fellow or a postdoctoral researcher. He will be supervised by Conboy; Tom Alber, professor of biochemistry; and David Schaffer, associate director of the Berkeley Stem Cell Center and professor of chemical engineering.
Adult stem cells have a receptor called Notch that, when activated, tells them that it is time to grow and divide, the researchers said. But stem cells also have a receptor for the protein TGF-beta that sets off a chain reaction activating the molecule pSmad3 and ultimately producing cyclin-dependent kinase (CDK) inhibitors, which regulate the cell's ability to divide.
"Interestingly, activated Notch competes with activated pSmad3 for binding to the regulatory regions of the same CDK inhibitors in the stem cell," said Conboy. "We found that Notch is capable of physically kicking off pSmad3 from the promoters for the CDK inhibitors within the stem cell's nucleus, which tells us that a precise manipulation of the balance of these pathways would allow the ability to control stem cell responses."
Notch and TGF-beta are well known in molecular biology, but Conboy's lab is the first to connect them to the process of aging, and the first to show that they act in opposition to each other within the nucleus of the adult stem cell.
Aging and the inevitable march towards death are, in part, due to the progressive decline of Notch and the increased levels of TGF-beta , producing a one-two punch to the stem cell's capacity to effectively rebuild the body, the researchers said.
"What we discovered is the interplay between two pathways - one an aging pathway, and the other a youthful pathway," said Conboy.
But what would happen if researchers blocked the adult stem cells in old tissues from reacting to those TGF-beta signals? The researchers put that question to the test in a living organism by comparing the muscle regeneration capacity of old, 2-year-old mice, comparable in age to a 75- to 80-year-old human, with that of 2-month-old mice, similar in age to a 20- to 25-year-old human.
For a group of the old mice, the researchers disabled the "aging pathway" that tells stem cells to stop dividing by using an established method of RNA interference that reduced levels of pSmad3. The researchers then examined the muscle of the different groups of mice one to five days after injury to compare how well the tissue repaired itself.
As expected, the researchers found that muscle tissue in the young mice easily replaced damaged cells with new, healthy cells. In contrast, the areas of damaged muscle in the control group of old mice were characterized by fibroblasts and scar tissue.
However, muscles in the old mice whose stem cell "aging pathway" had been dampened showed levels of cellular regeneration that were comparable to their much younger peers, and that were 3 to 4 times greater than those of the group of "untreated" old mice.
The researchers cautioned that shutting down the TGF-beta/pSmad3 pathway altogether by turning off the gene that controls it could lead to many health problems. The ability to suppress cell division is critical in controlling the development of tumors, for instance.
"When we are young, there is an optimal balance between Notch and TGF-beta," said Conboy. "We need to find out what the levels of these chemicals are in the young so we can calibrate the system when we're older. If we can do that, we could rejuvenate tissue repair for a very long time."
The researchers also warn against interpreting this research as the cure-all for aging.
"We're not at a point where we're ready to inject ourselves with TGF-beta antibodies and call it a day," said Carlson. "There are multiple mechanisms involved in how our body functions. We know that TGF-beta is involved in one aspect of aging, but we don't know where it fits in the global scheme of aging."
In addition to their work on adult stem cells, Carlson and Conboy have also discovered that human embryonic stem cells can actually neutralize the effects of aging. Conboy received funding last year from the California Institute for Regenerative Medicine (CIRM) to pursue this line of research.
Excellent post! That lady is right on the mark! I'm a PKTX stock holder that checks in here occasionally but have never posted because i was not a member. I specifically registered to comment on this post. She is so right! Also, you are correct in that you are the only poster here. Good luck to you.
(PKTX)..Being that I'am the only one posting on this site anymore and it's the weekend.. Time for a off-the-wall subject. A letter from an angry woman..
I don't know who wrote it but they should have signed it. Some powerful words. This woman should run for president.
Written by a housewife from New Jersey and sounds like it! This is one ticked off lady.
'Are we fighting a war on terror or aren't we? Was it or was it not started by Islamic people who brought it to our shores on September 11, 2001?
Were people from all over the world, mostly Americans, not brutally murdered that day, in downtown Manhattan , across the Potomac from our nation's capitol and in a field in Pennsylvania?
Did nearly three thousand men, women and children die a horrible, burning or crushing death that day, or didn't they?
And I'm supposed to care that a copy of the Koran was 'desecrated' when an overworked American soldier kicked it or got it wet?...Well, I don't. I don't care at all.
I'll start caring when Osama bin Laden turns himself in and repents for incinerating all those innocent people on 9/11.
I'll care about the Koran when the fanatics in the Middle East start caring about the Holy Bible, the mere possession of which is a crime in Saudi Arabia
I'll care when these thugs tell the world they are sorry for chopping off Nick Berg's head while Berg screamed through his gurgling slashed throat.
I'll care when the cowardly so-called 'insurgents' in Iraq come out and fight like men instead of disrespecting their own religion by hiding in mosques.
I'll care when the mindless zealots who blow themselves up in search of nirvana care about the innocent children within range of their suicide .
I'll care when the American media stops pretending that their First Amendment liberties are somehow derived from international law instead of the United States Constitution's Bill of Rights.
In the meantime, when I hear a story about a brave marine roughing up an Iraqi terrorist to obtain information, know this: I don't care.
When I see a fuzzy photo of a pile of naked Iraqi prisoners who have been humiliated in what amounts to a college-hazing incident, rest assured: I don't care.
When I see a wounded terrorist get shot in the head when he is told not to move because he might be booby-trapped, you can take it to the bank: I don't care.
When I hear that a prisoner, who was issued a Koran and a prayer mat, and fed 'special' food that is paid for by my tax dollars, is complaining that his holy book is being 'mishandled,' you can absolutely believe in your heart of hearts: I don't care.
And oh, by the way, I've noticed that sometimes it's spelled 'Koran' and other times 'Quran.' Well, Jimmy Crack Corn and-you guessed it-I don't care!!
If you agree with this viewpoint, pass this on to all your E-mail friends. Sooner or later, it'll get to the people responsible for this ridiculous behavior!
If you don't agree, then by all means hit the delete button. Should you choose the latter, then please don't complain when more atrocities committed by radical Muslims happen here in our great Country! And may I add:
'Some people spend an entire lifetime wondering if they made a difference in the world. But, the Marines don't have that problem' -- Ronald Reagan
I have another quote that I would like to add AND.......I hope you forward all this.
'If we ever forget that we're One Nation Under God, then we will be a nation gone under' Also by.. Ronald Reagan
One last thought for the day:
In case we find ourselves starting to believe all the Anti-American sentiment and negativity, we should remember England 's Prime Minister Tony Blair's words during a recent interview. When asked by one of his Parliament members why he believes so much in America , he said: 'A simple way to take measure of a country is to look at how many want in.. And how many want out.'
Only two defining forces have ever offered to die for you:
1. Jesus Christ
2. The American G. I.
One died for your soul, the other for your freedom.
Will PKTX even make it out of the starting gate before being acquired by a large Pharma??? My reading and doing some research on Bio-techs, it seems that with mergers, takeovers and acquisition on the rise..(imo)Is Protokinetixs next. Just a few articles in the Monday special of the Investor's Business Daily(unrelated articles but on mergers and acquisitions)show that there has been a big rise in the need to fill the voids, when products loose their patents.. Just a question asked?
Followers
|
72
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
12519
|
Created
|
04/05/04
|
Type
|
Free
|
Moderators Past and present sunspotter |
|
PROTOKINETIX INC.
CORPORATE OFFICE
412 Mulberry St,
Marietta Ohio 45750, USA
Tel: (304) 299-5070
EMAIL: contact@protokinetix.com
CEO:
Clarence E. Smith
BUSINESS MODEL
The biotechnology business is often subject to expensive and time consuming regulatory processes. Our approach is to expedite the development of our technology primarily through business relationships that provide us with leading-edge technical and marketing expertise to expedite the time lines to place products on the shelf.
ProtoKinetix is not about building a business with "bricks and mortar." We believe there are so many AAGP™ applications that can best be reached through strategic business relationships.
We assess each opportunity with return on investment as the priority. Defining and measuring each agreement based upon corporate investment, time line to market, strength of the organization within a specific market segment and marketing strengths.
As we build the value of AAGP™ we are also taking steps to generate revenue through sales of products in markets that do not require regulatory oversight.
COMMERCIAL APPLICATIONS
|
|
Ammendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada
August 27, 2020ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of January 24, 2020. We have now completed the sterilization, quality assurance, labeling of the AAGP® (PKX-001) and are ready to ship the final product to the University of Alberta upon receipt of the NOL from Health Canada for the continuation of the Phase 1 clinical trials.
PKX-001 is the designation given to the lead drug product molecule of the AAGP® family. Islet cell transplants are well recognized as a viable and effective treatment for Type-1 diabetes. The PKX-001 study will treat islet cells prior to transplantation into human test subjects. The clinical trials primary objective is the establishment of patient safety. The study will also be making observations related to indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells. The trial follows extensive preclinical evaluation in experimental models (to learn more, refer to this link:Diabetes).
The trial is being led by Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet and Living Donor Liver Transplant Programs, Canada Research Chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta.
Dr. James Shapiro Bio
Dr. James Shapiro Video
About the Edmonton Protocol
Diabetes Research Institute Foundation Canada Video
To obtain additional information and updates regarding this trial please use the following link: Clinicaltrials.gov – Islet Transplantation Using PKX-001.
See the promising research of AAGP® and results to date.
Visit our new website at ProtoKinetix.com for more information and to join our email list.
***COVID-19 Information as Applicable to ProtoKinetix***
In December 2019, the 2019 novel coronavirus (“COVID-19”) surfaced in Wuhan, China. The World Health Organization declared a global emergency on January 30, 2020, with respect to the outbreak and several countries, including the United States, Japan and Australia have initiated travel restrictions to and from China. The impacts of the outbreak are unknown and rapidly evolving.
Although we rely on third-party suppliers and manufacturers in China to produce AAGP® for testing, we believe we have sufficient quantities to last the Company for the next two years. Nevertheless, this outbreak has resulted in the extended shutdown of certain businesses, which may in turn result in disruptions or delays to our supply chain and restrictions on the export or shipment of our products.
Further, we cannot predict the availability of our scientists to continue testing or whether the trials can be completed. A widespread health crisis could adversely affect the global economy, resulting in an economic downturn that could impact demand for our products.
To date the outbreak has not had a material adverse impact on our operations. However, the future impact of the outbreak is highly uncertain and cannot be predicted and there is no assurance that the outbreak will not have a material adverse impact on the future results of the Company. The extent of the impact, if any, will depend on future developments, including actions taken to contain COVID-19.
During recent testing at The University of British Columbia, where photo receptors were transplanted into animal models, it was observed that AAGP® may have had a role in protecting xenografts and allografts from immune rejection from the host immune system, thereby helping the graft to survive and mature in the transplant recipient.
Immune rejection, leading to graft versus host disease (GVHD) is a primary concern present in almost all transplants, requiring the use of immunosuppressants such as cyclosporin, tacrolimus and rapamycin.
In addition to filing for patent protection, ProtoKinetix has started a major study at Dalhousie University to examine the effects of AAGP® in transplant medicine.
By protecting this technology, the Company is in a better position to move forward with its research in organ transplantation.
“We are pleased to protect this patent as we can now license the rights to other companies to develop different applications of the AAGP® lead compound,” said Clarence E. Smith, president and chief executive officer.
****Please visit our new website at ProtoKinetix.com for more information and to join our email list.
http://www.protokinetix.com
|
|
|
|
|
|
ProtoKinetix AAGP(R) Dry Eye Therapy Program Launched
11/22/19
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces the initiation of a program testing AAGP(R), to develop a potential therapy to treat Dry Eye Disease (DED). AAGP(R) has repeatedly demonstrated anti-inflammatory and cytoprotective properties, and also exhibits pharmaceutical properties beneficial for topical formulations.
The eye is extremely sensitive, so before efficacy testing can commence an eye irritation study will be conducted in accordance with both industry and regulatory requirements. This testing has been contracted to ITR Laboratories of Montreal who are a well-recognised CRO in this area. This testing is scheduled to commence in early December with results before January 2020.
About ITR Laboratories
In anticipation of a successful result from ITR Laboratories, EyeCRO, from Oklahoma City, have been contracted to conduct the efficacy testing. This testing will involve topical application of AAGP(R) and evaluations of its effects on ocular inflammation. EyeCRO are world recognised, specialised CRO in the field of pre-clinical ocular drug research and development. This program will commence in early January 2020 and is expected to run for 3-4 months.
About EyeCRO
About Dry Eye Disease
Dry Eye Disease is a condition in which a person does not have enough quality tears to lubricate and nourish the eye. Tears are necessary for maintaining the health of the front surface of the eye and for providing clear vision. Dry Eye Disease is a common and often chronic problem, particularly in older adults. This condition currently afflicts more that 30-million Americans (430-million people globally) and can affect as much as 40% of the population for various reasons. The dry eye disease ophthalmic market is very active, with $7.7 billion in revenues and a current growth of 12.5% CAGR.
Tests Show AAGP® Preserved and Enabled Retinal Cells to Mature Without Compromise after 5-Month Milestone
ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) updates shareholders regarding ongoing 3rd stage testing of retinal cell replacement therapy at the University of British Columbia. As previously reported, the Company has demonstrated the ability of AAGP® to protect transplanted cells in a pre-clinical experimental model of retinal degeneration. For the purpose of these tests, the animals had a functioning immune system and so were treated with immune modulating drugs to model clinical practices. The results clearly demonstrated the ability of AAGP® to protect the delicate transplanted cells from the stress of the local microenvironment after transplant into the recipient at the four-week timepoint. Two questions under study have been answered:
In order to answer these essential questions, a comprehensive series of tests using immune suppressed animal models were designed. These tests included a long-term follow-up out to six months to determine if the cells continued to mature into photo-sensitive cells and whether the presence of AAGP® interfered with this essential development. At the five-month timepoint, the tests show that AAGP® preserved and allowed these cells to mature without compromise.
Pluripotent stem-cell therapy guided into retinal cells could potentially cure blindness even in the late stages of disease. However, until now, studies in animals have shown that too few transplanted retinal cells survive the hostile local environment long enough to integrate correctly into the retina’s complex neural circuitry. The AAGP® molecule in this study has overcome this considerable obstacle for stem-cell treatments that aim to replace retinal cells.
These studies are a critical component of the pre-clinical testing required to advance this program into clinical trials. The study is being conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.
“We are now completing functional studies in two different animal models. These include electrical responses of the eye and also a behavioral test of sharpness of vision. Preliminary results show retention of vision function particularly in behavioral testing in the rodent model. Also, of note, we have not documented any adverse effects in animals when using AAGP®. Although our results are in relatively small numbers of animals (a dozen in each cohort of testing) this bodes exceptionally well for any proposed future clinical trial work.”
– Dr. Kevin Gregory-Evans
Dr. Kevin Gregory-Evans Video on AAGP®
Dr. Gregory-Evans Bio
|
|
|
|
Agreement Secured by ProtoKinetix to Start Heart Research Product Validation Studies
May, 09 2019
MARIETTA, Ohio--(BUSINESS WIRE)-- ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is announcing that the Company has secured a partnership agreement with IMPART investigator team Canada at Dalhousie University and has now commenced studies to reveal the benefits of PKX-001 (AAGP®) in cardiac metabolism. These studies will determine the efficacy of PKX-001 as a cardioprotectant and will be led by Diabetes Canada Scholar, Dr. Thomas Pulinilkunnil. As the director of the IMPART cardiometabolic research program, Dr. Pulinilkunnil leverages extensive training in molecular and metabolic sciences from his training at the University of British Columbia, the University of Alberta Heart Institute and Harvard Medical School. Dr. Pulinikunnil is currently a tenured Associate Professor at Dalhousie University, Faculty of Medicine in the Department of Biochemistry and Molecular Biology. Dr. Pulinilkunnil will utilize sophisticated techniques and experimental models of type-2 diabetes, cardiac ischemia, and cardioncology to evaluate the therapeutic utility of PKX-001 as a cardioprotectant.
Cardioprotectants are used extensively in hospital settings when the circulation is bypassed. They are components of cardioplegia solutions that protect the heart of patients from ischemia (low blood flow), such as during open-heart surgery or in preparation for heart transplantation. The metabolic protection identified in work-to-date by research laboratories using the ProtoKinetix product, AAGP®, as part of the Company’s product development strategy, has also opened up the potential for therapeutic protection of the heart during chemotherapy. Cardioncology is an emerging field of interest globally, as the cure rates of chemotherapy continue to improve and extend life. Ensuring that the heart is safe during chemotherapy is of paramount importance to several treatments regimens.
“I am very optimistic that our program will determine the therapeutic utility of PKX-001 as a cardioprotective molecule and I am confident that our team will identify, at least in part, some of the molecular mechanisms involved in the functionality of PKX-001. Glycopeptides, such as these, are inherently fascinating to me because they were inspired by the natural world. As such, the fundamentals have already been established biologically in nature in demonstrating their ability to self-protect tissues from harmful conditions like cold temperatures, low oxygen, and exposure to toxic agents. Developing innovative therapies inspired by fundamental science is exciting to me and our research team.” – Dr. Thomas Pulinilkunnil
About IMPART investigator team Canada
IMPART is a growing consortium of scientists and clinicians that are collaborating to better understand the common threads of chronic disease related molecular pathophysiology. The team seeks to deliver innovative medical solutions through research, development, and clinical trials. The focus of this consortium is to address the unmet medical needs of special populations and medical conditions involving inflammation, metabolism, and physical abilities through research translation. The team is particularly concerned with vulnerable patients, as they have the most to gain from new medical innovations. The team uses an interdisciplinary approach to develop research questions, as well as uncover and deploy novel solutions for unmet medical needs.
ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) updates its stockholders regarding phase 3 of testing using AAGP® in retinal cell replacement therapy at the University of British Columbia.
The study is now using 2-animal models and a significantly larger number of animals in both control and AAGP® treated groups for a longer time frame. Until this study, the longest a group was tested for was 4-weeks. In this study, the lab currently has animals at the 3-month mark. All animals are reported to be healthy and behaving normally. Early results from this intensive program are expected to be presented to the Company by the end of July 2019. This study is being conducted to test whether AAGP® treated cells continue to develop into retinal cells. If successful, this may potentially lead towards the restoration of vision in humans.
This procedure could become a critical approach for the treatment of retinal diseases including Age-Related Macular Degeneration (AMD). The study is being conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.
The global ophthalmic therapeutics/drug market is expected to reach USD $35.7 billion by 2025, according to a new report by Grand View Research, Inc.
The retinal replacement program is just one of several ongoing studies involving our AAGP® molecule. Other ongoing studies are for:
|
|
***PKTX...ProtoKinetix Releases Second in a Series of Scientific Update Videos
January 16, 2019
MARIETTA, Ohio--(BUSINESS WIRE)--ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the launch of the second in a series of informational videos by the Principal Investigators in each field currently being tested.
The second video is an update on the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due to the positive results from the first two phases of testing where the AAGP® treated cells showed a dramatic increase in survivability versus untreated cells over a four-week period, we are now expanding the study. The new study shall include two animal models over a longer period of time to test whether the AAGP® treated cells continue to develop into retinal cells to potentially restore vision in humans. The study is being conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.
Dr. Kevin Gregory-Evans on AAGP™http://protokinetix.com/videos/
ProtoKinetix Releases First in a Series of Scientific Update Videos
December 19, 2018
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces the launch of the first in a series of informational videos by the Principal Investigators in each field currently being tested.
The first video is an update on the clinical trial of AAGP™ PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type 1 diabetes led by Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet and Living Donor Liver Transplant Programs, Canada Research Chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta.
Dr. James Shapiro on AAGP™
Click here for more on Dr. Shapiro and the Edmonton Protoco
****Here's a link.. http://protokinetix.com/videos/
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) Is pleased to announce the launch of a proof of concept study in the field of cardiovascular sciences.
Dr. Thomas Pulinilkunnil, Associate Professor, Department of Biochemistry and Molecular Biology, Dalhousie University is the principal investigator on this project. Pulinilkunnil laboratory will screen and examine the therapeutic utility of PKX-001 (AAGP®) against inflammatory, hypertrophic and ischemic pathologies in the heart . Upon the completion of this phase of testing, pre-clinicalscreening of organ preservation and metabolic effects of PKX-001 will be undertaken in transplant ready cardiac tissue. The overarching goal of this project is to develop PKX-001 as a cardioprotective agent with wide ranging applications in cardiovascular medicine.
ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care Solutions
September 4, 2018
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX)
ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBCPress Release..
08/10/2018
ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has entered into the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due to the positive results from the first two phases of testing where the AAGP® treated cells showed a dramatic increase in survivability versus untreated cells over a four-week period, we are now expanding the study. The new study shall include two animal models over a longer period of time to test whether the AAGP® treated cells continue to develop into retinal cells to potentially restore vision in humans. The study conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.
Dr. Gregory-Evans Bio
The studies to date demonstrated that in vitro pre-treatment of PPCs with 4 mg/mL PKX-001 resulted in a substantial increase of cell survival following their transplantation into the subretinal area of immunocompromised rabbits with retinal degeneration. PPCs treated with PKX-001 maintained their ability to express key proteins associated with photoreceptor functions.
Based on the outstanding results thus far, ProtoKinetix now has patents pending in the United States of America, Canada and Europe.
ProtoKinetix will now extend its previous studies into further in vivo functional studies. To date we have histological data ex vivo and in vivo that PKX-001 improves PPC survival and that these cells mature to express proteins of mature photoreceptors.
The global ophthalmic therapeutics/drug market is expected to reach USD $35.7 billion by 2025, according to a new report by Grand View Research, Inc.
|
ProtoKinetix Has Entered into a Research Agreement with The University of British Columbia to Test the Effect of its AAGP™ on Monoclonal Antibody Production and Bone Marrow Recovery
January 10, 2018
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is pleased to announce that it has entered into a research agreement with The University of British Columbia (UBC), under the direction of principal investigator Dr. Kelly McNagny, Professor, Faculty of Medicine, Department of Medical Genetics.
Dr. Kelly McNagny Bio
This research agreement is to test and determine the effect of AAGP™ on monoclonal antibody production and bone marrow recovery.
The University of British Columbia’s Antibody Lab will test whether AAGP™ enhances the production of monoclonal antibodies from cell lines, an important manufacturing issue for current immunotherapies. UBC will also test whether AAGP™ enhances the survival/efficacy of engraftment of hematopoietic stem cells, a technical hurdle in cell based therapies for bone marrow transplantation and cancer therapy.
The goal will be to determine whether AAGP™ enhances the ex vivo survival and maintenance of multipotent potential in a way that could be used to enhance bone marrow transplantation. “If AAGP™ could enhance survival or, better still, aid in the expansion of stem cells in vitro, this would be of enormous clinical benefit” – said Dr. Kelly McNagny, Professor of Medical Genetics, UBC.
The goal of a bone marrow transplant is to cure many diseases and types of cancer. When the doses of chemotherapy or radiation needed to cure a cancer are so high that a person’s bone marrow stem cells will be permanently damaged or destroyed by the treatment, a bone marrow transplant may be needed. Bone marrow transplants may also be needed if the bone marrow has been destroyed by a disease.
A bone marrow transplant can be used to:
Replace diseased, non-functioning bone marrow with healthy functioning bone marrow (for conditions such as leukemia, aplastic anemia, and sickle cell anemia).
Regenerate a new immune system that will fight existing or residual leukemia or other cancers not killed by the chemotherapy or radiation used in the transplant.
Replace the bone marrow and restore its normal function after high doses of chemotherapy and/or radiation are given to treat a malignancy. This process is often called rescue (for diseases such as lymphoma and neuroblastoma).
Replace bone marrow with genetically healthy functioning bone marrow to prevent further damage from a genetic disease process (such as Hurler's syndrome, adrenoleukodystrophy or severe combined immunodeficiency (SCID)).
BIOGRAPHY - DR. KELLY MCNAGNY
Dr. Kelly McNagny obtained his Ph.D. in Cellular Immunology at the U. of Alabama at Birmingham in 1990. There he worked with Dr. Max D. Cooper (Howard Hughes Medical Institute, National Academy of Sciences) and his research focused on cell surface proteins that regulate B cell maturation and homing. He then moved to the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany where he performed his postdoctoral studies in the lab of Dr. Thomas Graf from 1991 to 1996. There his work focused on transcriptional control of hematopoietic stem cell maturation and cell fate. He performed some of the first studies to identify transcription factors that regulate the gene expression and differentiation of eosinophils, which are known to play a major role in allergic and asthmatic responses. In addition, he identified a number of novel hematopoietic stem cell surface proteins (the CD34 family) and began analyzing their function. He continued his studies at the EMBL as a semi-independent, Visiting Scientist from 1996 to 1998 prior to starting his own laboratory at The Biomedical Research Centre, at UBC.
He is currently a full professor in Medical Genetics at The Biomedical Research Centre where his work focuses on stem cell behavior, inflammatory disease, cancer biology and therapeutics.
In 2015 he also served as the Scientific Director of the Centre for Drug Research and Development (CDRD), a National Centre of Excellence aimed at translating early stage scientific discoveries into therapies.
He has garnered several awards including the 2004 Showell-Pfizer Junior Faculty Award from the American Association for Immunology, a MSFHR Career Investigator Award and a visiting professorship at the Phillip's University of Marburg. Kelly is a member of the Canadian Stem Cell Network Centre of Excellence (Sub-Chair of the Trainee Education Committee), Associate Director of the AllerGen Network Centre of Excellence, and Co-Director of AllerGen'sBiomarkers and Bioinformatics Platform.
***The Effects of ProtoKinetix’ Anti-Aging Glycopeptide (AAGP™) on Immune Cell Banking and Functions Relevant to
Immunotherapy
November 16, 2017
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is pleased to provide a scientific update on immune cell banking and functions relevant to immunotherapy using AAGP™ in collaboration with Proactive Immune Sciences. Earlier in 2017, Proactive initiated a research program which utilized an anti-aging glycopeptide (AAGP™) produced by ProtoKinetix Inc. which, amongst other uses, has shown the potential to benefit various cells during cryopreservation. In this research program, Proactive is investigating whether the AAGP™ produced by ProtoKinetix Inc. improves survival and function of cryopreserved immune cells by focusing on the following objective:
1) Assessment of the effect of AAGP™ on cryopreserved immune cell viability and functionality.
Immune based interventions represent one of the fastest growing, most promising areas of personalized medicine. This is particularly true for cancer, which is largely a disease of immune failure. Therefore, there is a strong impetus for individuals to bank healthy immune cells at as early an age as possible, before these cells are compromised by infection, malignancy, or simply advanced immunological age. Proactive Immune Sciences Corporation will collect and cryopreserve all of the different types of immune cells present in blood for its clients. These cells can be used later for any form of immunotherapy the client might require. These cells can also be used for immune system regeneration to help restore an immune system that is compromised from chemotherapy or radiation treatments or even old age. Although cryopreservation of cells is commonly performed, Proactive would like to offer its clients the most advanced methods to ensure their cells are in optimal conditions for the processing required for these immunotherapies.
In May 2017, Proactive, with the support of the National Research Council of Canada (NRC) through an Industrial Research Assistance Program (IRAP) Grant, began testing AAGP™ in the cryopreservation process used to store Peripheral Blood Mononuclear Cells (PBMC). Cells were frozen using Proactive’s cryopreservation “cocktail” along with various concentrations of AAGP™.
A combination of Proactive’s cryopreservation “cocktail” and AAGP™ resulted in a 45% increase in viability of PBMCs over that of Proactive’s cryopreservation “cocktail” alone. When T and B cells were isolated from the frozen PBMCs post-thaw, both cell types displayed greater viability as well. These positive results were repeated with JURKAT cells, a T cell line used for research.
These findings have significance for immune cell based therapies. A 45% increase in the viability of PBMCs through the freezing process will result is significantly more cells being available should they be needed later for immune system reconstitution, requiring far less blood to be drawn. For patients, whose immune systems have been compromised from chemotherapy and/or radiation therapies, it could mean that they would now be able to participate in immune based therapies for which they previously could not provide enough viable cells.
Improved viability of T and B cells in the presence of Proactive’s cryopreservation “cocktail” and AAGP™ may provide a better starting material for the processing involved in several cellular therapies in development or recent approval such as CAR-T therapy for cancer.
The next phase of our research will explore the impact of Proactive’s cryopreservation “cocktail” and AAGP™ on functions of the immune cells pertinent to these developing cellular therapies.
About Proactive Immune Sciences
Proactive stores (banks) immune cells, while people are healthy, for them to use later in life should they contract cancer or have other immune system related diseases.
Having the rights to AAGP™ for immune cell cryopreservation enables Proactive to establish a unique foothold in the cell banking market and to provide services to other organizations that use frozen immune cells in their therapeutic processes.
OTC Disclosure & News Service
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is pleased to provide a scientific update to its stockholders. The Company is exploring the following areas for the use of its AAGP™ family of molecules:
Presently at the University of Alberta:
1. Diabetes (study started February 2017)
The PKX-001 (AAGP™’s clinical name) Study is treating islet cells prior to transplantation into human test subjects. The clinical trials are assessing any side effects or physiological damage to the test subjects. The study is looking for indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells.
The clinical trials are well underway and will continue throughout the end of the year with enrollment of up to ten patients. To obtain additional information and updates regarding the trials please use the following link: Clinicaltrials.gov - Islet Transplantation Using PKX-001.
2. Kidney Ischemia (anticipated start date 4th quarter 2017)
Ischemia is a condition that occurs when blood flow to cells, tissues or organs is severely restricted. This condition can affect any part of the human body. When this circumstance transpires, cell death and organ damage follows very rapidly. Ischemia is a major cause of kidney damage, heart attacks and strokes.
Our testing is to determine whether AAGP™ can reduce the inflammatory response that causes cell damage and organ failure that occurs during an ischemic attack.
3. Normothermic Liver Perfusion (start date to be determined)
Normothermic (body temperature), ex vivo (outside the body) liver perfusion (method of irrigation) is an innovative therapy applied to donor livers outside of the body before transplantation that improves organ quality and makes organs that were previously unsuitable safe for transplant.
Our planned testing is to determine the beneficial effects of adding AAGP™ to the perfusate solution. Perfusate solutions are used to protect donor organs from the period of harvest until transplantation. We hope to evidence that AAGP™ can extend the viable life of harvested transplant organs.
Presently at the University of British Columbia:
1. Retinal Cell Replacement (started June 2016)
The research program at the University of British Columbia, under the guidance of Dr. Gregory-Evans will be determining whether AAGP™ can help improve the survival of stem cells that are currently being used in human trials to treat retinal blindness. We are doing this because of the poor outcome in the current state of play using stem cells in the treatment of blindness. Proof of principal work has been done in animal models but these successes are few and far between. What has been seen most recently is that probably as few as 10% of injected cells are surviving more than a week. Although this is adequate for proof of principle work, it is not good enough for developing a clinical medical treatment. We are looking for ways to improve cell survival in actual living eyes.
The study conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia compared the results of transplanted retinal precursor cells with and without the addition of AAGP™. The cells treated with AAGP™ showed a dramatic improvement on cell survivability and viability, functionality compared to the untreated cells. Ongoing testing is now being conducted to determine if these transplanted cells are fully functioning.
2. Monoclonal Antibody Production (anticipated start date 4th quarter 2017)
Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope. The use of monoclonal antibodies to treat diseases is called immunotherapy because each type of monoclonal antibody will target a specific targeted antigen in the body. Monoclonal antibodies are currently being used to treat Cancer, Rheumatoid Arthritis, Multiple Sclerosis, Cardiovascular Disease, Systemic Lupus Erythematosus, Crohn's Disease, Ulcerative Colitis, Psoriasis, Transplant Rejection, and several more conditions.
By adding AAGP™ into the culture medium, we are hoping to show a substantial increase in viable monoclonal antibodies that could lead to a dramatic decrease in the cost of production of monoclonal antibody medicines.
We are working at initiating programs on:
1. Bone Marrow Recovery (preliminary stage)
Bone marrow is the flexible tissue in the interior of bones. In humans, red blood cells are produced by cores of bone marrow in the heads of long bones in a process known as hematopoiesis. It can be collected and cryopreserved. Conditions that can be treated by transplantation include bone marrow diseases, histiocytic disorders, hemoglobin opathies, inherited immune system disorders, inherited metabolic disorders, leukemias and lymphomas, myelodysplastic syndromes, multiple myeloma, plasma cell disorders, other cancers and malignant diseases.
We will be testing to prove the viability and functionality of cryopreserved bone marrow increases with the addition of AAGP™.
2. Cord Blood Preservation (preliminary stage)
Cord blood is the blood left in the umbilical cord and placenta immediately after a baby is born. It can be collected, stored and used at any time during a baby’s lifetime to treat a wide variety of diseases and medical conditions. Cord blood is currently being used to treat multiple forms of cancer, hematopoietic diseases, inborn errors of metabolism and immune system diseases.
We will be testing to prove the viability and functionality of cryopreserved cord blood cells increases with the addition of AAGP™.
3. Ischemic Stroke Repair (anticipated start 4th quarter 2017)
Ischemic Stroke is usually associated with severe disabilities, high recurrence rate and other poor outcomes. Currently, there are no long-term effective treatments for stroke. Cell therapies have been explored previously. However, the therapeutic outcomes are often limited by poor survival of transplanted cells, difficult delivery, uncontrolled cell differentiation, ineffective engraftment with host tissues and non-sustained delivery of growth factors.
We will be testing to demonstrate that the AAGP™ molecule suppresses the inflammatory attack caused by ischemic stroke thereby preventing any long term damage to the human body.
Proactive Immune Sciences is conducting research on:
1. Immune Cell Cryopreservation Recovery (started June 2017 - anticipated end date 4th quarter 2017)
Immune based interventions represent one of the fastest growing, most promising areas of personalized medicine. This is particularly true for cancer, which is largely a disease of immune failure. Therefore, there is a strong impetus for individuals to bank healthy immune cells at as early an age as possible, before these cells are compromised by infection, malignancy, or simply advanced immunological age. The ability to use immune cells provides an oncologist another major tool in their arsenal to fight cancer.
Results to date have been very encouraging. We are hoping to prove the functionality of cryopreserved immune cells increases with the addition of AAGP™ on the immune cell cryopreservation protocols used by Proactive Immune Sciences.
“We are delighted that research continues to support a growing belief in the potential benefits of AAGP™ for an expanding spectrum of medical applications. Through our international partnerships and academic relationships, we continue to explore and participate in well-designed scientific studies in support of a fundamental understanding of how AAGP™ can benefit numerous medical conditions. We are encouraged by the growing clinical data to support the effectiveness of AAGP™. I look forward to updating our stockholders with additional results as they become available as well as releases that will give a better understanding as to why we are conducting the study.” - Clarence E. Smith, President and Chief Executive Officer.
ST. MARYS, W. Va.--(BUSINESS WIRE)--ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) and Proactive Immune Sciences (www.proactiveimmunesciences.com) today announce that they have entered into a joint research collaboration. The goal of the research will be to test the effect of the patented anti-aging glycopeptide AAGP™ on the immune cell cryopreservation protocols used by Proactive Immune Sciences.
“We welcome the opportunity to show the effectiveness of our AAGP™ molecule in another rapidly expanding, high-demand, commercial arena, further demonstrating the versatility of this molecule’s ability to protect cells in different clinical situations”
“We are excited about this new joint research collaboration and hope AAGP™ has some of the same positive effects, with respect to cryopreserving immune cells, that it is having on other cell lines,” says Jeff Schulz, CEO, Proactive Immune Sciences. “We are hoping to prove through our research that AAGP will have a positive affect on helping immune cells recover from the cryopreservation process. Any improvement in cell survival rate, or cell function could have significant, positive benefits for future treatments using cryopreserved immune cells.
Pending a successful outcome of our research, the intent is for Proactive to enter into a licensing agreement with ProtoKinetix for the cryopreservation of immune cells. This will give Proactive customers the benefit of knowing their stored immune cells will perform at the highest levels possible should they require them for any immune cell based cancer or immune system reconstitution later in their life.”
The initial phase of the research is expected to conclude later in 2017. Partial funding for the project has been provided by The National Research Council’s Industrial Research Assistance Program.
About the National Research Council's Industrial Research Assistance Program
Immune based interventions represent one of the fastest growing, most promising areas of personalized medicine. This is particularly true for cancer, which is largely a disease of immune failure. Therefore, there is a strong impetus for individuals to bank healthy immune cells at as early an age as possible, before these cells are compromised by infection, malignancy, or simply advanced immunological age. These cells can be used later on for any form of immunotherapy the client might require.
“We welcome the opportunity to show the effectiveness of our AAGP™ molecule in another rapidly expanding, high-demand, commercial arena, further demonstrating the versatility of this molecule’s ability to protect cells in different clinical situations,” said Clarence Smith, President, CEO and Chairman of the Board of ProtoKinetix.
|
2017-02-07
Company Website: http://www.protokinetix.com
ST. MARYS, W. Va. -- (Business Wire)
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) updates its stockholders on the testing of neuronal retinal cells in living tissue at the University of British Columbia (“UBC”) under the guidance of Dr. Gregory-Evans.
As explained by Dr. Gregory-Evans, the research program at UBC will be determining whether AAGP™ can help improve the survival of stem cells that are currently being used in human trials to treat retinal blindness. We are doing this because of the poor outcome in the current state of play using stem cells in the treatment of blindness. Proof of principal work has been done in animal models but these successes are few and far between. What has been seen most recently is that probably as few as 10% of injected cells are surviving more than a week. Although this is adequate for proof of principle work, it is not good enough for developing a clinical medical treatment. We are looking for ways to improve cell survival in actual living eyes.
The researchers at UBC have reached the conclusion that AAGP™ should provide the required level of protection to ensure post-engraftment survival. One reason is theoretical and one is experimental. The theoretical basis is that when tissue is damaged, that tissue breaks down and releases toxins into its environment. We believe that AAGP™ can work to reduce the harmful effects of these toxins. Based on previous tests conducted by the Company, AAGP™ has demonstrated significant anti-inflammatory properties. The experimental basis for our hypothesis is that we have tested the drug in tissue culture in the lab and found that it improves the survival of cells.
The current work that we are doing is taking those results and that theory and looking at it now in living tissue to see if we can reproduce the successes that we achieved before. We have established a new type of model for retinal degeneration in a rabbit and are currently working on injecting neuronal cells plus AAGP™ to see if we can see any improvement long term in how these cells survive and integrate into the retina and hopefully lead to vision restoration in the animals.
“We hope to achieve results in experiments more closely aligned with human disease. If that is the case the molecule could become a major advance in the field of stem cells and blindness.” Dr. Kevin Gregory-Evans, Professor of Ophthalmology in the Faculty of Medicine, University of British Columbia
Acute medical research study is always progressing, but one of the problems that researchers rely on is the benefit from solutions that can deal with the fundamental factors of inflammation and oxidation. Both are well-known causes of life-threatening conditions and diseases, and accelerated aging. In addition many acute medical problems are benefiting from cell therapies and transplantation of cell, tissues and organs.
AAGP™ is now being used or investigated as a possible solution by many healthcare companies that specialize in medical cell therapies, organ transplant, trauma, blood product banking and anti-inflammation.
AAGP™ has taken Protokinetix's research team into preservation of stem cells and cell therapy, storage of blood platelets and blood products, harvesting and transplantation of islet cells for diabetes treatments, time sensitive organ transplantation and inflammation causing diseases and conditions.
Protokinetix expects to license several commercial applications from its AAGP™ family as well as expand its ongoing research and development with institutions and businesses. Protokinetix is actively in talks with several healthcare companies that are testing the molecule in their specific niche applications.
ST. MARYS, W. Va.--(BUSINESS WIRE)--ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) today announced that the Governors of the University of Alberta have received a “No Objection Letter” from Health Canada to its Clinical Trial Application entitled: “Clinical Study using Antiaging Glycopeptide (PKX-001) in Islet Transplantation”. This authorization will allow the clinical trial group to enroll patients into the study. The study will test the effects of using PKX-001 (designation given to the drug product AAGP™ molecule) on islet cells treated prior to transplantation into human test subjects as an addition to the already established Edmonton Protocol for the treatment of Type 1 Diabetes.
“We have been very fortunate to have worked with ProtoKinetix on a series of highly compelling bench-top studies with their anti-aging glycopeptide compound AAGP™ in our islet research lab. Based on that data, and the early exciting finding that AAGP™ can protect human islets in a powerful way against both the stress of engraftment and toxic effects of antirejection drugs, we have now reached a pivotal step of beginning human trials in the clinic. The trial is approved and we now eagerly await the early results in patients. If the findings translate to the clinic in a manner that reflects the preclinical studies, AAGP™ has the potential to substantially improve outcomes in patients receiving islet transplants today, and future stem cell therapies.” Dr. James Shapiro, M.D., Ph.D., FRCSC, Director of Clinical Islet Transplant Program, University of Alberta.
Click for Dr. James Shapiro Bio
“This is a major milestone for ProtoKinetix as we advance our lead development program into clinic trials and affirms our ability to meet development timelines. This would not have been possible without the participation and dedication of not only our management team but also the team at the University of Alberta. My sincere thanks to them all.” Clarence Smith, President, CEO and Chairman of the Board of ProtoKinetix.
About the PKX-001 Study
PKX-001 is the designation given to the drug product molecule of the AAGP™ family. Islet cell transplants are well recognized as a viable and effective treatment for T1 diabetes. The PKX-001 Study will treat islet cells with PKX-001 prior to transplantation into human test subjects. The clinical trials will be assessing any side effects or physiological damage to the test subjects. The study will also be looking for indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells. The trail follows extensive preclinical evaluation in animal models.
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) today announced that the Governors of the University of Alberta have submitted an Investigational Testing Authorization application to commence clinical studies in Canada. This authorization will allow the clinical trial group to enroll Canadian patients into the study.
"Based on extensive experiments in the lab we are clearly excited to take forward the AAGP(TM) molecule from the bench to testing in patients in partnership with ProtoKinetix. This anti-aging glycopeptide molecule has been exceedingly potent in protecting human islets from early damage after transplant from engraftment and anti-rejection drugs in our preliminary tests, and if these promising findings can be replicated in patients in the clinic receiving islet cell transplants today, and potentially stem cells in the future, this would represent a major advance." Dr. James Shapiro, M.D., Ph.D., FRCSC, Director of Clinical Islet Transplant Program, University of Alberta.
Dr. James Shapiro
"It is a remarkable achievement for a small biotech company like ProtoKinetix to be submitting a Clinical Trial Application (CTA) to Health Canada." Julia Levy, PhD, Chairman ProtoKinetix Business and Scientific Advisory Board.
Dr. Julia Levy
"I look forward to the opportunity to prove that AAGP(TM), used in the Edmonton Protocol, will greatly improve results in the treatment of Type 1 Diabetes in humans. I am very pleased that we have met the goals that we set out in January, 2016." Clarence Smith, President, CEO and Chairman of the Board of ProtoKinetix.
About the PKX-001 Study
PKX-001 is the designation given to the drug product molecule of the AAGP(TM) family. Islet cell transplants are well recognized as a viable and effective treatment for T1 diabetes.
The PKX-001 Study will treat islet cells prior to transplantation into human test subjects. The clinical trials will be accessing any side effects or physiological damage to the test subjects. The study will also be looking for indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells.
ProtoKinetix, Incorporated is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP(TM)) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has submitted an Investigational Testing Authorization application to Health Canada to enter into a Phase 1/2 human clinical trial at the University of Alberta. Additional studies will be expanded to include whole organ transplantation and other cell therapies used in regenerative medicine.
ProtoKinetix, Incorporated Clarence E. Smith, 304-299-5070 President and Chief Executive Officer csmith@protokinetix.com Twitter: @ProtoKinetix
ST. MARYS, W.Va.--(BUSINESS WIRE)--Jun. 7, 2016-- ProtoKinetix, Incorporated (OTCQB:PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix’ AAGP™ has been published in the Journal of Tissue Engineering and Regenerative Medicine and is available online at:
Anti-ageing glycoprotein promotes long-term survival of transplanted neurosensory precursor cells
AAGP™, an antifreeze glycopeptide, has been demonstrated to significantly improve the viable yield of stem cells transplanted in retinal tissue at the University of British Columbia under the guidance of Dr. Kevin Gregory-Evans.
ProtoKinetix has entered into a research agreement with the University of British Columbia to research neuronal cell transplantation as an extension of the studies recently published by Dr. Gregory-Evans in the Journal of Tissue Engineering and Regenerative Medicine.
Regarding the new studies, IN VIVO STUDIES TO DETERMINE THE POTENTIAL OF ANTI-AGING GLYCOPROTEIN (AAGP™) IN ENHANCING THE LONGTERM SURVIVAL OF NEURAL STEM CELLS, Dr. Gregory-Evans explains: “My research team at the University of British Columbia is very excited to move on to the next stage of our studies with ProtoKinetix’ compound AAGP™. We have shown that it is useful, in a simple model system, at promoting stem cell survival in tissue transplantation experiments. The next stage is now to move into animal model systems. This is for three reasons, first because it will give us a better quantitative understanding of AAGPs™ effectiveness, that is not only will it show us if AAGP™ works but also how well in might work in humans. Second, it will show us if there are any toxicity concerns in our target tissue (the central nervous system) and third as a regulatory requirement before undertaking human studies. Our major interest is blinding eye disease and stroke. We will study AAGP™ in models of both these common central nervous system ailments with the hope that, all going well, we can move on to early clinical studies in human sufferers within the next five years. Tissue transplantation promises to revolutionize the medicine of tomorrow and we think AAGP™ will be an important part of this revolution.”
ProtoKinetix is also pleased to report that it has received the assignment of the patents for the use of AAGP™ in retinal cell transplantation.
Journal of Tissue Engineering and Regenerative Medicine is a multidisciplinary journal that publishes research and reviews on the development of therapeutic approaches which combine stem/progenitor cells with biomaterials and scaffolds, and growth factors and other bioactive agents. The journal focuses on the development of biological functional substitutes that restore, maintain, or improve tissue or organ function. The publication carries an Impact Factor of 5.199.
ProtoKinetix, Incorporated is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing the company is now preparing a submission to enter into a Phase 1/2 human clinical trial at the University of Alberta. Additional studies will be expanded to include whole organ transplantation and other cell therapies used in regenerative medicine.
ST. MARYS, W.Va.--(BUSINESS WIRE)--May 2, 2016-- ProtoKinetix, Incorporated (OTCQB:PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix’ AAGP™ has been accepted by the Journal of Tissue Engineering and Regenerative Medicine for publication. The date of publication is unknown at this time but should be available online in advance of the printed version. AAGP™, an antifreeze glycopeptide, has been demonstrated to significantly improve the viable yield of stem cells transplanted in retinal tissue at the University of British Columbia under the guidance of Dr. Kevin Gregory-Evans.
Dr. Gregory-Evans concluded that embryonic cells treated with AAGP™ and transplanted into retina tissue, an accepted model for the central nervous system, compared to the control group not treated was 300% more viable.
Dr. Gregory-Evans proposes that AAGP™ works by inhibiting toxic signaling from surrounding necrotic tissue. Necrotic tissue is dead tissue, which usually results from an inadequate local blood supply. Necrotic tissue contains dead cells and debris that are a consequence of the fragmentation of dying cells.
”AAGP™ could be a huge benefit to the future of Pre-clinical and Clinical transplantation medicine,”said Dr. Kevin Gregory-Evans. He added,“AAGP™ will revolutionize transplantation medicine across the board.”
The significance of these results may have far reaching implications. In addition to cell, tissue and organ transplantations, there are strong implications that AAGP™ may have powerful applications for the treatment of stroke and heart attack treatment.
Dr. Kevin Gregory-Evans is currently Professor of Ophthalmology in the Faculty of Medicine, University of British Columbia, and holder of the Julia Levy BC Leadership Chair in Macular Research, Vancouver, Canada.
Dr. Gregory Evans' Bio is too extensive to repeat in full on this press release-his full Bio can be found at: http://protokinetix.com/about/kevin-gregory-evans/.
Journal of Tissue Engineering and Regenerative Medicine is a multidisciplinary journal that publishes research and reviews on the development of therapeutic approaches which combine stem/progenitor cells with biomaterials and scaffolds, and growth factors and other bioactive agents. The journal focuses on the development of biological functional substitutes that restore, maintain, or improve tissue or organ function. The publication carries an Impact Factor of 5.199.
ProtoKinetix, Incorporated is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing the company is now preparing a submission to enter into a Phase 1/2 human clinical trial. Additional studies will be expanded to include whole organ transplantation and other cell therapies used in regenerative medicine.
ST. MARYS, W.Va.--(BUSINESS WIRE)--Apr. 26, 2016-- ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) outlines the steps to be completed for the application to conduct a clinical trial in Canada.
For the last four years ProtoKinetix has been involved in a collaboration with the Laboratory of Dr. James Shapiro, M.D., Ph.D., FRCSC, the director of the Clinical Islet Transplant Program at the University of Alberta Hospital. The outcome of these extensive tests resulted in a publication this February in the prestigious American Diabetes Association Journal, Diabetes and a planned submission to Health Canada of a clinical trial application (CTA). The CTA, for a Phase 1/2 study in patients, will involve the addition of AAGP™ to the well-established Edmonton Protocol for islet cell transplants for the treatment of type 1 diabetes.
Before a CTA can be submitted several rigorous tests and events have to be completed.
1. The molecule being tested has to be produced under current Good Manufacturing Practice (GMP) guidelines. GMP is an exacting standard of production that requires a validated and documented approach for each step of the process and a complete provenance for every component.
2. A Pharmacokinetic (PK) analysis with a validated methodology has to be completed on the molecule to determine AAGP™’s absorption and distribution throughout the human body.
3. The molecule has to be tested for toxicology, including evaluation of the genotoxic potential.
4. The end product must be certified as sterile.
5. An Investigator's Brochure has to be prepared incorporating these results as well as the Chemistry, Manufacturing, & Control (CMC) documentation provided by the GMP facility.
The CTA submission will be an Investigator-sponsored application from Dr. James Shapiro’s Laboratory.
In order to assist the Company in achieving a cost effective and timely CTA submission, ProtoKinetix has retained the services of the following experts and Contract Research Organizations (CROs):
Evelina Rubinchik PhD
Dr. Rubinchik is our contracted toxicologist who is organizing theselection of nonclinical CROs and management of toxicological studies. Dr. Rubinchik is also involved in the preparation of project budgets and timelines, review, and interpretation of toxicological data.
Dana Nohynek MSc, RAC
Ms. Nohynek is an independent regulatory consultant with expertise in Clinical Trial Application submissions and liaising with the Canadian regulatory authority.
PK Analysis CRO
BRI Biopharmaceutical Research Inc. is a specialized analytical, LC/MS/MS bioanalytical and DM/PK contract research organization (CRO) servicing pharmaceutical and biotechnology companies in discovery, preclinical and clinical programs supporting IND and Toxicology CROs.
Toxicology CRO
ITR Canada Inc. is an international contract research organization that provides non-clinical toxicology services for the biotechnology and pharmaceutical industries with clients located around the globe. Operating in Montréal since 1989, ITR’s purpose-built preclinical research facility was designed to be optimized for quality technical and scientific research. A privately-held organization with more than 300 employees in Canada, ITR offers personalized services from planning and study program design to study implementation and reporting for regulatory drug filing. ITR Canada is CCAC and AAALAC accredited, and studies conducted are fully compliant with GLP.
Manufacturing CRO
AmbioPharm, Inc. (APi) is a full-service peptide manufacturing company headquartered in North Augusta, SC, USA. In its cGMP manufacturing facilities in the USA and Shanghai, China, it develops highly efficient processes for manufacturing peptides at small to very large scale as Active Pharmaceutical Ingredients used in New Chemical Entities and generic peptides by clients worldwide.
Fiscal 2015 was a year of significant progress for ProtoKinetix, Incorporated. We executed several complex initiatives and continued to make great strides in delivering the strategic initiatives to improve the fiscal health of the Company and to further the scientific advancement of the AAGP™ molecule. Overall, the company’s regulatory status, financial position and scientific foundation for commercial growth are all stronger today than they were a year ago.
Our company has recently been restructured to improve efficiency and to enable growth and value to our stockholders. We have a new management team comprised of some old and some new faces. The team members are:
Clarence E. Smith President and CEO
Susan M. Woodward, CFO
Edward P. McDonough, Director and Head of Audit Committee
Peter Jensen, Head Consultant Business Advisory Board
Julia Levy, Head Consultant Scientific Board
Grant Young, Head Consultant Research and Development
The financial position of ProtoKinetix has never been stronger. Since June of 2014 all past overdue filings with the Securities Exchange Commission have been brought up to date. We received a Full Revocation Order on February 23, 2015 from the British Columbia Securities Commission in regards to its previously implemented Cease Trade Order issued on May 9, 2013. During this time period, ProtoKinetix negotiated a debt settlement with Standard Bankcorp resulting in a gain on settlement of $192,000.
All US tax returns have been filed from 1999 to 2014 and ProtoKinetix has been accepted to both the Offshore Voluntary Disclosure Program and the Domestic Voluntary Disclosure Program to comply with US tax law.
As of June 8th, ProtoKinetix began trading on the OTCQB® Venture Marketplace under the symbol "PKTX." The Company was formerly trading on the OTC Pink® marketplace under the same symbol.
We were pleased to acquire a portion of certain patents and all rights associated therewith from the University of Alberta pursuant to a Royalty Agreement entered into on or about April 8, 2015.
ProtoKinetix has had positive changes to our Balance Sheet as follows:
Account | Balance 12/31/14 | ProjectedBalance12/31/15 |
Change | ||||||
Cash | 317 | 360,000 | 359,683 | ||||||
Debt | 818,143 | 135,000 | (683,143) | ||||||
Shares | 175,662,433 | 216,602,433 | 40,940,000 | ||||||
Assets | 65,000 | 65,000 |
Our cash position increased by $359,683 due to an increase in private placements. Debt decreased by $683,143 due to settlement of all long and short term debts. We issued 40,940,000 shares of our common stock in connection with private placements, consulting agreements and settlement of debt. Assets increased by $65,000 due to the acquisition of patents.
Our CFO, Susan M. Woodward noted, “During this current year we have made great strides in placing ProtoKinetix to be in a much more favorable position to allow the Company to move forward and keep stride with the blossoming scientific advances of our AAGP™ molecule. I look forward to our continued success in 2016 with the support of our current and future stockholders as well as the dedication of our management and consulting team.”
This year ProtoKinetix had notable achievements of which we are very proud. AAGP™ was presented at the Congress of the International Pancreas and Islet Transplant Association in Melbourne, Australia in November. We also completed an intense, 3-year islet transplantation study with the University of Alberta. Currently, we have completed a peer review and have been published in the prestigious, American Diabetes Association’s Journal: Diabetes. We are continuing to study the effects of AAGP™ on Non-Obese Diabetic mice at the Dr. James Shapiro Lab in Edmonton at the University of Alberta.
We are, at present, preparing a clinical trial application to Health Canada. This trial will be conducted by the Shapiro team at the University of Alberta on the well-established, Edmonton Protocol used for treatment of Type 1 Diabetes through islet cell transplants.
As part of this submission, the company has:
Commissioned AmbioPharm, Inc. to produce AAGP™ under strict GMP (Good Manufacturing Practice) standards. GMP is required by Health Canada and US FDA (United States Food and Drug Administration) for human use. Toxicity testing will be conducted by a third party. Pharmacokinetics and Pharmacodynamics (PK/PD) has been addressed by BRI Labs in Vancouver. PK/PD studies the absorption rate and quantities of drugs through the human body.We are looking forward to moving ahead with our application for clinical trials in the coming year. We anticipate testing on the effects of this molecule on the preservation of whole donor organs and tissues for transplantation.
In closing, I want to thank our Board of Directors, the Business and Scientific Advisory Board and the rest of the ProtoKinetix team, whose creativity, hard work and dedication have made this year’s achievements possible. Our strong relationship with Dr. James Shapiro and his scientific team continues to be a key asset in following our path to commercialization. We have a unique opportunity to make a difference and we are well prepared to meet our corporate needs for 2016 and pursue continued growth and maximize stockholder value.
Dec 17, 2015
ST. MARYS, W. Va. -- (Business Wire) --
ProtoKinetix, Incorporated (OTCQB:PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that their molecule, AAGP, an antifreeze glycopeptide that mimics a naturally occurring glycoprotein found in Arctic fish is helping to significantly improve the efficacy of Cell Transplant Treatments for diabetes - a procedure that transplants insulin producing islet to render them insulin independent for periods of time.
Anti-Aging GlycoPeptide (AAGP), is the focus of a new study published in the journal Diabetes. Researchers from the University of Alberta's Faculty of Medicine & Dentistry found that by soaking islet cells in AAGP for an hour and then washing it off prior to transplantation, the cells were protected from tacrolimus an antirejection drug commonly used during transplants that is toxic to islets cells.
Normally when we expose human islets to tacrolimus in the petri dish, they flat line and don?t release insulin at all, says James Shapiro, senior author of the study and Canada Research Chair in Transplant Surgery and Regenerative Medicine at the U of A. When we add the AAGP and wash it all off, the cells work perfectly normally, and are protected in a remarkably durable manner. We find we need far fewer cells to treat diabetes in our preclinical models than we would normally.
Since his creation of the Edmonton Protocol in 1999, more than 250 patients have been treated by Shapiro through islet cell transplantation. A key challenge of the procedure though is that most patients typically need two islet infusions, each prepared from a separate pancreas organ donor. Shapiro says there aren't enough organ donors to meet demand. Through the use AAGP, a greater number of islet cells will survive the procedure, potentially allowing more patients to be treated.
Just a one hour soak in AAGP is enough to protect the islet cells for up to a month or two afterwards. It has a very potent and profound effect, says Shapiro. As a direct result of these findings, we're now moving forward with plans for a first in human clinical trial?led at the University of Alberta?testing this drug in our human islet cell transplant program.?
This synthetic molecule seems to provide significant protection to cells exposed to multiple deleterious conditions, such as UV radiation, starvation, extreme temperatures andoxidative stress, says Boris Gala-Lopez, lead author of the study and a clinical/research fellow at the U of A's Department of Surgery. We are certainly very excited for the multiple opportunities this finding entails to the field of transplantation research.
Funding for the study was provided by the Diabetes Research Institute Foundation of Canada, while the drug AAGP was provided by ProtoKinetix.
We are very excited to have our AAGP molecule showcased in this prestigious journal. We are also extremely confident in the ongoing success of our collaboration with Dr. James Shapiro and his outstanding team said Clarence Smith, President, CEO and Chairman of the Board of ProtoKinetix.
If proven successful in human clinical trials, Shapiro believes the inclusion of AAGP could soon become a permanent addition to the Edmonton Protocol representing a significant step forward in the treatment of Type 1 diabetes through islet transplantation. While more research is needed, he also believes the drug shows promise for a wide range of transplantations?potentially working to protect organs as effectively as it protects islets.
ST. MARYS, W. Va.--(BUSINESS WIRE)--Sep. 10, 2015-- ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that AAGP™ will be presented at the 2015 Joint Congress of the IPITA-IXA-CTS onMonday, November 16, 2015.The Joint Congress of the International Pancreas and Islet Transplant Association (IPITA), the International Xenotransplantation Association (IXA) and the Cell Transplant Society (CTS) to be held in Melbourne, Australia, 15–19 November 2015.
Dr. Boris L. Gala-Lopez, Research Fellow of Department of Surgery in the Alberta Diabetes Institute at the University of Alberta will be giving a lecture titled “Anti-aging Glycopeptide Protects Human Islets Against Tacrolimus-related Injury and Facilitates Engraftment” to support his conclusion that, “Supplementation with AAGP™ during the culture period improves islet quality and potency. Upon transplantation, pre-treatment with AAGP™ may facilitate engraftment in mice, improve graft secretory function and may attenuate long-term tacrolimus induced graft dysfunction. These findings may constitute a clear opportunity to develop more efficient strategies against post-transplant diabetes mellitus.”
For details see the web site: confman.melbourne2015.org/mobis/lecture/758
About Dr. Boris L. Gala-Lopez
Dr. Gala-Lopez is currently a PhD Research Fellow in the Clinical Islet Transplant Program at the University of Alberta. He has been responsible for multiple preclinical and clinical investigations in the field of islet transplantation to improve the novel treatment for Type 1 diabetes mellitus.
Dr. Gala-Lopez has also done extensive work in the area of ischemia-reperfusion injury for cell and solid organ transplantation.
09/18/2015
ST. MARYS, W. Va.--(BUSINESS WIRE)--Sep. 18, 2015-- ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that it has begun testing NOD (Non Obese Diabetic) mice with its AAGP™ molecule at the James Shapiro laboratory at the University of Alberta.
Type 1, diabetic NOD mice with AAGP™ versus a control group of Type 1, diabetic NOD mice without AAGP™ will be monitored for their blood-glucose levels. Using the NOD mice as a model the Edmonton team will be specifically assessing the potentially protective effect of AAGP™ against the antibody attack conducted against the islet cells in the pancreas.
NOD Mice, like the Bio-Breeding rat, are used as an animal model for Type 1 diabetes. Non-obese diabetic (NOD) mice exhibit a susceptibility to spontaneous development of autoimmune insulin dependent diabetes mellitus (IDDM).The NOD strain and related strains were developed at Shionogi Research Laboratories in Aburahi, Japan by Makino and colleagues and first reported in 1980.The group developed the NOD strain by an outbreeding of the cataract-prone strain from JcI:ICR mice.
At the conclusion of these tests, the internal organs of the NOD mice will be examined for any evidence of toxicity and bioavailability. This data is an extremely valuable step on the critical path towards submissions to Health Canada or the FDA for human clinical trial applications.
About the James Shapiro Laboratory
The James Shapiro Laboratory is active experimental laboratory working on improving long term survival of transplanted islets, and in immunomodulation of transplanted tissues. He is Principal Investigator on several NIH and JDRF-funded clinical trials, including clinical testing of costimulation blockade in islet transplantation.
About ProtoKinetix
ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release may contain statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150918005068/en/
Source: ProtoKinetix, Inc.
ProtoKinetix, Inc.Clarence E. Smith, President & Chief Executive Officer304-299-5070csmith@protokinetix.com
06/05/2015
ST. MARYS, W.Va.--(BUSINESS WIRE)--Jun. 5, 2015-- ProtoKinetix, Incorporated(OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that CEO Clarence Smith recently returned from visiting Dr. James Shapiro at the University of Alberta. Mr. Smith met with Dr. Shapiro and his impressive team, including Dr. Boris Gala-Lopez. As previously announced, the Company has been heavily involved with the James Shapiro Laboratory for the last 24-months. Dr. Shapiro’s team has conducted extensive tests on islet cell transplantation using the AAGP™ molecule for the treatment of diabetes using AAGP™. Mr. Smith was impressed with the program and gratified that AAGP™ was proving to be a central element in the research.
Dr. Shapiro is a professor of surgery, medicine and surgical oncology. He is director of the Clinical Islet Transplant Program and the Living Donor Liver Transplant Programs at the University of Alberta. He is also principal investigator of National Institute of Health and the Juvenile Diabetes Research Foundation clinical trials. In addition to these positions, he is the leader of the Project 1 - Ex-vivo Organ Transplant Protection and Repair Program of the Canadian National Transplant Research Program.
Due to the excellent results of these tests on islet cell transplantation with AAGP™, Dr. Shapiro and his team are expanding their field of investigation to include:
1) Whole Organ Preservation
a. A major initiative of the Canadian National Transplant Research Program (CNTRP).
b. Preservation of hearts, lungs, kidneys, livers and transplantable tissue has become of critical importance to transplantation medicine.
2) Non Obese Diabetes (NOD) Mice
a. NOD mice are used as an animal model for Type 1 Diabetes testing.
b. Dr. Shapiro’s team shall be exploring the potential of AAGP™ to delay the progression of this disease.
“This impressive team of transplant surgeons and scientists have made clear to me the dramatic scope of applications that our family of molecules possess,” said Clarence E. Smith, President and Chief Executive Officer.
About ProtoKinetix
ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150605005032/en/
Source: ProtoKinetix, Inc.
ProtoKinetix, Inc.Clarence E. Smith, 304-299-5070President and CEO
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |